BSEInsider Trading / SAST26 Sept 2026 · 26 Sept 2026, 05:20 pm
The trading window of the Company shall remain closed for all the Designated Persons (including their immediate relatives) of the Company from October 01, 2026 till completion of 48 hours from the announcement of the unaudited financial results of the Company for the quarter and half year ending September 30, 2026, to the Stock Exchanges. The date of meeting of the Board of Directors to approve the unaudited financial results of the Company for ....
Panacea Biotec Ltd · 531349
✦ AI Summary
Panacea Biotec Ltd has announced the closure of its trading window for designated persons from October 1, 2026, until 48 hours after the announcement of unaudited financial results for the quarter and half year ending September 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk2/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Panacea Biotec Ltd - 531349 - Closure of Trading Window
Attachments (1)
📄pdf
Download →
cdeeca99-5667-4655-9358-2605fbdfe0bc.pdf
View document text
September 26, 2026
The Manager, Listing Department BSE Limited
The National Stock Exchange of India Ltd. Corporate Relationship Department,
Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers,
Bandra (E), Mumbai - 400 051 Dalal Street, Mumbai - 400 001
NSE Symbol: PANACEABIO BSE Scrip Code: 531349
Sub: Intimation of closure of Trading Window
Dear Sir/Madam,
Pursuant to the Company’s Code of Conduct for Prevention of Insider Trading framed in
accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time
to time, we would like to inform that the trading window of the Company shall remain closed for
all the Designated Persons (including their immediate relatives) of the Company from October 01,
2026 till completion of 48 hours from the announcement of the unaudited financial results of the
Company for the quarter and half year ending September 30, 2026, to the Stock Exchanges.
The date of meeting of the Board of Directors to approve the unaudited financial results of the
Company for the quarter and half year ending September 30, 2026, shall be informed in due course.
This is for your kind information and record please.
Thanking you,
Sincerely yours,
for Panacea Biotec Limited
Ankit Jain
General Manager – Legal & Company Secretary
Panacea Biotec Limited (CIN: L33117PB1984PLC022350)
Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab
Correspondence/Corporate office : B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com